Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-07, Vol.7 (27), p.41172-41185
Main Authors: Fleurence, Julien, Cochonneau, Denis, Fougeray, Sophie, Oliver, Lisa, Geraldo, Fanny, Terme, Mickaël, Dorvillius, Mylène, Loussouarn, Delphine, Vallette, François, Paris, François, Birklé, Stéphane
Format: Article
Language:English
Subjects:
Adult
Aged
Animals
Antibodies, Monoclonal - therapeutic use
Apoptosis - immunology
Cancer Vaccines - therapeutic use
Cell Line, Tumor
Female
Gangliosides - immunology
Gangliosides - metabolism
Glioblastoma - immunology
Glioblastoma - metabolism
Glioblastoma - therapy
Humans
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Middle Aged
Molecular Targeted Therapy - methods
Research Paper
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.9226